¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Morphogenetic Protein Receptors, Type II"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • different membrane protein
    À¯°ü¸·´Ü¹éÁú
  • extracellular matrix protein
    ¼¼Æ÷¹Ù±ù¹ÙÅÁÁú´Ü¹éÁú, ¼¼Æ÷¿Ü±âÁú´Ü¹éÁú
  • endogenous protein
    ³»ÀδܹéÁú
  • foreign protein
    ÀÌÁ¾´Ü¹éÁú
  • glial fibrillary acidic protein
    ¾Æ±³¼¼Æ÷¼¶À¯»ê¼º´Ü¹éÁú, ±³¼¶À¯»ê¼º´Ü¹éÁú
  • globular protein
    °ø¸ð¾ç´Ü¹éÁú, ±¸»ó´Ü¹éÁú
  • heat-shock protein
    ¿­Ãæ°Ý´Ü¹éÁú
  • heterologous protein
    ÀÌÁ¾´Ü¹éÁú
  • high-protein diet
    °í´Ü¹éÁú½Ä»ç
  • human plasma protein fraction
    »ç¶÷Ç÷Àå´Ü¹éºÐÀ²
  • iron binding protein
    ö°áÇմܹéÁú
  • major basic protein
    ÁÖ¿ä±âÃʴܹéÁú, ÁÖ±âÀú´Ü¹éÁú
  • mitogen-activated protein kinase
    ¹ÌÅä°ÕȰ¼ºÈ­´Ü¹éÁúŰ³ª¾ÆÁ¦
  • monocyte chemotactant protein
    ´ÜÇÙ±¸È­Çнò¸²´Ü¹éÁú, ´ÜÇÙ±¸È­ÇÐÁÖ¼º´Ü¹é
  • matrix protein
    ¹ÙÅÁÁú´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • type culture
    Ç¥ÁرÕÁ¾
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î
  • disorganized type schizophrenia
    ºØ±«Á¤½ÅºÐ¿­º´
  • dromedary type
    ´ÜºÀÇü
  • dysplastic type
    Çü¼ºÀÌ»óÇü
  • expansive type
    °ú´ëÇü
  • extroverted type
    ¿ÜÇâÇü
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • hebephrenic type schizophrenia
    ÆÄ°úÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,delayed-type
    Áö¿¬Çü(òÀæÅû¡)
  • hypersensitivity reactions,type i(anaphylactic)
    IÇü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
  • hypersensitivity, delayed-type
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • hypersensitivity, immediate-type
    Áï½ÃÇü °ú¹Î¹ÝÀÀ
  • hypertrophic type
    ºñ´ëÇü
  • hypogammaglobulinemia, Swiss-type
    ½ºÀ§½ºÇü °¨¸¶±Û·ÎºÒ¸°ÀúÇ÷Áõ
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
  • personality, type A
    AÇü ÀΰÝ
  • personality, type B
    BÇü ÀΰÝ
  • phage type
    ÆÄÁöÇü(¡­úþ).
  • phage type
    ÆÄÁöÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • glial fibrillary acidic protein
    ½Å°æ±³¿ø¼¶À¯(Îïê«àéë«)»ê(ß«)´Ü¹é
  • globular protein
    ±¸»ó´Ü¹é(Áú)(¡­Ó±ÛÜòõ).
  • glucose transport protein unit
    Æ÷µµ´ç ¿î¹Ý ´Ü¹é ´ÜÀ§(GLUT)
  • guanosine triphosphate-activating protein
    »ïÀλ걸¾Æ³ë½Å Ȱ¼º´Ü¹éÁú
  • halogen protein
    ÇÒ·ÎÀü´Ü¹éÁú(¡­Ó±ÛÜòõ).
  • hbx-protein
    HBx´Ü¹é
  • heat shock protein
    ¿­Ãæ°Ý´Ü¹éÁú
  • heat shock protein
    ¿­Ãæ°Ý ´Ü¹éÁú
  • heat shock protein
    ¿­Ãæ°Ý ´Ü¹é
  • heat-shock protein
    ¿­-Ãæ°Ý´Ü¹é
  • heterologous protein
    ÀÌÁ¾´Ü¹é.
  • high protein diet
    °í´Ü¹é½Ä(ÀÌ)(ÍÔÓ±ÛÜãÝìÈ).
  • immune protein
    ¸é¿ª´Ü¹éÁú.
  • inner membrane protein
    ³»¸·´Ü¹éÁú
  • insoluble protein
    ºÒ¿ë¼º ´Ü¹é(Áú).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Articular surface for navicular bone
    ¹ß¹è°üÀý¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ°üÀý¸é
  • Navicular bone
    ¹ß¹è»À
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ
  • Tuberosity of navicular bone
    ¹ß¹è»À°ÅÄ£¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñÁ¶¸é
  • Head of metatarsal bone
    ¹ßÇ㸮»À¸Ó¸®
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñµÎ
  • Body of metatarsal bone
    ¹ßÇ㸮»À¸öÅë
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñü
  • Base of metatarsal bone
    ¹ßÇ㸮»À¹Ù´Ú
    [¿¾ ¿ë¾î] ÁßÁ·(ô)°ñÀú
  • Irregular bone
    ºÒ±ÔÄ¢»À
    [¿¾ ¿ë¾î] ºÒ±ÔÄ¢°ñ
  • Canaliculus of bone
    »À¸ð¼¼°ü
    [¿¾ ¿ë¾î] °ñ¼Ò°ü
  • Bone matrix
    »À¹ÙÅÁÁú
    [¿¾ ¿ë¾î] °ñ±âÁú
  • Lacuna of bone
    »À¹æ
    [¿¾ ¿ë¾î] °ñ¼Ò°­
  • Trabecula of bone
    »ÀÀܱâµÕ
    [¿¾ ¿ë¾î] °ñ¼ÒÁÖ
  • Lamella of bone
    »ÀÃþÆÇ
    [¿¾ ¿ë¾î] °ñÃþÆÇ
  • Fibrous bone marrow
    ¼¶À¯°ñ¼ö [¼¶À¯»À¼ÓÁú]
    [¿¾ ¿ë¾î] ¼¶À¯¼º°ñ¼ö
  • Reticulofibrous periosteal bone
    ¼¼¸Á¼¶À¯»À¹Ù±ù¸·»À
    [¿¾ ¿ë¾î] ¼¼¸Á¼¶À¯¼º°ñ¸·°ñ
  • Triquetral bone
    ¼¼¸ð»À
    [¿¾ ¿ë¾î] »ï°¢±Ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • chimeric protein
    Ű¸Þ¶ó ´Ü¹éÁú(Ó±ÛÜòõ)
  • cholesterol ester transfer protein
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅÍ ÀüÀ̴ܹéÁú(ï®ì¹Ó±ÛÜòõ)
  • coat protein
    ¿ÜÇǴܹéÁú(èâù«Ó±ÛÜòõ)
  • competitive protein-binding technique
    °æÇÕÀû ´Ü¹éÁú °áÇÕ¼ú(ÌæùêîÜÓ±ÛÜòõÌ¿ùêâú)
  • complete protein
    ¿ÏÀü´Ü¹éÁú(èÇîïÓ±ÛÜòõ)
  • conjugated protein
    Á¢ÇմܹéÁú(ïÈùêÓ±ÛÜòõ)
  • contractile protein
    ¼öÃ༺ ´Ü¹éÁú(â¥õêàõÓ±ÛÜòõ)
  • copper protein
    µ¿´Ü¹éÁú(ÔÞÓ±ÛÜòõ)
  • core protein
    ÇٽɴܹéÁú(ú·ãýÓ±ÛÜòõ)
  • corticosteroid-binding protein
    "ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ), (ÔÒ) transcortin"
  • cortisol-binding protein
    ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ) (ÔÒ) transcortin
  • C-protein
    C ´Ü¹éÁú (Ó±ÛÜòõ)
  • C-reactive protein
    C¹ÝÀÀ(Úãëë) ´Ü¹éÁú(Ó±ÛÜòõ)
  • CRO protein
    CRO ´Ü¹éÁú (Ó±ÛÜòõ)
  • crystal protein
    °áÁ¤ ´Ü¹éÁú(Ì¿ïÜÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • pubic bone
    Ä¡°ñ
  • reactive bone excrescence
    ¹ÝÀÀ¼º°ñµ¹Ãâ
  • resorption of bone
    °ñÈí¼ö
  • scaphoid bone
    ¼Õ¹è°ñ, ÁÖ»ó°ñ
  • sclerotic bone island
    °æÈ­¼º°ñ¼¶
  • sesamoid bone
    Á¾ÀÚ°ñ
  • solitary bone cyst
    °í¸³°ñ³¶
  • sphenoid bone
    Á¢Çü°ñ
  • spongy bone
    ÇØ¸é»À, ÇØ¸é°ñ
  • temporal bone
    ÃøµÎ°ñ
  • trapezium bone
    Å«¸¶¸§°ñ, ´ë´ÉÇü°ñ
  • trapezoid bone
    ÀÛÀº¸¶¸§°ñ, ¼Ò´ÉÇü°ñ
  • triangular bone
    »ï°¢°ñ
  • zygomatic bone
    °ü°ñ, Çù°ñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CBP calcium-binding protein; carbohydrate-binding protein; cardiopulmonary bypass; chlorobiphenyl; cobal...
CP candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta...
CRP chronic relapsing pancreatitis; corneal-retinal potential; coronary rehabilitation program; C-reacti...
CSP carotid sinus pressure; cavum septi pellucidi; cell surface protein; cerebrospinal protein; Chartere...
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GRPR Gastrin-releasing peptide receptors
hPR Human progesterone receptors
IPR Imidazolines Preferring Receptors
IFN-gamma R Interferon gamma receptors
KIR Killer cell Ig-like Receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • iris-type
    ȫä ¸ð¾ç
  • Jaeger's test type
    ¿¹°Å ¹®ÀÚ
    ½Ã·Â °Ë»ç¿¡ »ç¿ëµÇ´Â ´ë¼ÒÀÇ ¹®ÀÚ¸¦ ´Ã¾î³õÀº Ç¥.
  • jealous type
    ÁúÅõÇü
  • knife edge type
    ³ªÀÌÇÁ ¿¡Âî ŸÀÔ
    finishing lineÀÇ ÀÏÁ¾ÀÌ´Ù.
  • lepromatous type
    ³ªÁ¾Çü
  • localized type
    ±¹¼ÒÇü
  • major type
    ÁÖµÈ ÇüÅÂ
  • membrane type
    ¸·Çü
  • mesial step type
    ±Ù½É °è´ÜÇü
  • mobile type diagnostic X ray apparatus
    À̵¿Çü Áø´Ü X¼± ÀåÄ¡
  • monocytic type
    ´ÜÇÙ±¸Çü
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • multifocal type
    ´Ù¹ß¼º
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
receptors, dopamine d2 A class of dopamine receptors identified by their binding profiles for synthetic ligands, their molecular biology, and, perhaps, their mode of action.
(12 Dec 1998)
receptors, drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.
(12 Dec 1998)
receptors, eicosanoid Cell surface proteins that bind eicosanoids with high affinity and trigger intracellular changes influencing the behaviour of cells. Among the eicosanoid receptors are receptors for the prostaglandins, thromboxanes, and leukotrienes.
(12 Dec 1998)
receptors, endothelin Cell surface proteins that bind endothelin with high affinity and trigger intracellular changes which influence the behaviour of cells.
(12 Dec 1998)
receptors, epidermal growth factor-urogastrone Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors.
(12 Dec 1998)
receptors, erythropoietin Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, estradiol Cytoplasmic proteins that bind estradiol, migrate to the nucleus, and regulate DNA transcription.
(12 Dec 1998)
receptors, fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognise and combine with the fc (crystallizable) portion of immunoglobulin molecules.
(12 Dec 1998)
receptors, fibroblast growth factor Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
(12 Dec 1998)
receptors, fibronectin Specific sites or molecular structures on or in cells with which fibronectins react or to which they bind. Studies have shown that these receptors function in certain types of adhesive contact as well as playing a major role in matrix assembly. These are the traditional fibronectin receptors, also called vla-5 receptors or alpha 5 beta 1 integrins. There are also other integrins that bind fibronectin, including alpha v beta 1.
(12 Dec 1998)
Receptors for activated C Kinase Synonym for endosome.
(18 Nov 1997)
receptors, fsh Cell surface proteins that bind follicle-stimulating hormone (follitropin, fsh) with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, gaba Cell-surface proteins that bind gaba with high affinity and trigger changes that influence the behaviour of cells. Gaba-a receptors control chloride channels formed by the receptor complex itself. They are blocked by bicuculline and usually have modulatory sites sensitive to benzodiazepines and barbiturates. Gaba-b receptors act through g-proteins on several effector systems, are insensitive to bicuculline, and have a high affinity for l-baclofen.
(12 Dec 1998)
receptors, gaba-a Cell surface proteins which bind gaba and control an integral membrane chloride channel. Gaba-a receptors are the most prevalent inhibitory neurotransmitter receptors in the brain. Several isoforms have been cloned, and they belong to a superfamily which includes nicotinic receptors, glycine receptors, and 5ht-3 receptors. Most gaba-a receptors have separate modulatory sites sensitive to benzodiazepines and to barbiturates.
(12 Dec 1998)
receptors, gaba-b Cell surface proteins which bind gaba and influence cells via interactions with g-proteins. Gaba-b receptors are pharmacologically characterised by their insensitivity to the blocker bicuculline and sensitivity to the agonist l-baclofen. They are found both presynaptically and postsynaptically, and act variously by inhibition of adenylate cyclase, activation of phospholipase a2, activation of potassium channels, and inactivation of voltage-activated calcium channels.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á